Biomarkers to Guide MBC Treatment Decisions: dMMR/MSI-H, TMB, and NTRK Fusion - Metastatic Breast Cancer Trial Talk

From the Experts

A biomarker is a gene, protein, or molecule produced by the body or tumor in a person with cancer that tells a doctor something about the cancer cells. MBC experts studied biomarkers to develop new recommendations for doctors on how to use biomarker information to carefully make MBC treatment decisions.

This month, we continue with the second post in our 3-part series explaining 3 biomarkers in these new recommendations: deficient mismatch repair/microsatellite instability (dMMR/MSI-H), tumor mutational burden (TMB), and NTRK fusion.

People who participated in clinical trials helped contribute to the strong evidence that supports these recommendations. Clinical trial participation continues to be important to gather new information about other biomarkers that do not have strong evidence for recommendations.

Click the links below to read about the new biomarker recommendations, how the dMMR/MSI-H, TMB, and NTRK fusion biomarkers help doctors make treatment decisions, and about current clinical trials related to these biomarkers.

Biomarkers for Guiding MBC Treatment
 dMMR/MSI-H Biomarker
 TMB Biomarker
 NTRK Biomarker

Last Modified on December 1, 2022

Tags:

SEARCH OUR SITE

for past articles or specific information.